Murine cytomegalovirus vaccine vectors for administration to non-mouse subjects
By using replication-deficient MCMV vector and ie2 gene disruption technology, the antigen-specific immune response is induced in non-mouse hosts, solving the problem of restricted antigen delivery during repeated administration of existing vaccine vectors, and achieving multiple infections Robust immune protection for sexual diseases and cancers improves the safety and effectiveness of vaccines.
Patent Information
- Application Number
- CN202380018788.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-28
- Filing Date
- 2023-01-25
- Publication Date
- 2024-11-15
AI Technical Summary
Existing viral vector vaccines are restricted due to vector-specific neutralizing antibodies during repeated administration, and are unable to effectively induce robust immune responses to a variety of infectious diseases and cancers, especially in non-mouse hosts. vaccine vector.
Using replication-deficient murine cytomegalovirus (MCMV) vectors, expressing the use of replication-deficient murine cytomegalovirus (MCMV) vectors by deleting or destroying the immediate early 2 (ie2) gene in non-mouse subjects, thus using it as a vaccine vector in humans or veterinary medicine. Disease antigens are used to induce antigen-specific immune responses and ensure effective expression of antigens through inducible and constitutive promoters.
Achieve the induction of robust and persistent antigen-specific immune responses in non-mouse hosts, avoid vector replication and spread, provide long-term immune protection for a variety of infectious diseases and cancers, reduce the need to strengthen immunity, and increase The safety and effectiveness of the vaccine.
Smart Images

Figure GDA0005076392410000261 
Figure GDA0005076392410000271 
Figure GDA0005076392410000281
Abstract
Description
Technical Field
[0001] The present invention relates to the field of viral vectors and their use in inducing antigen-specific immune responses in subjects.
[0002] The present invention relates to the use of a replication-defective murine cytomegalovirus (MCMV) vector for inducing an antigen-specific immune response in a subject, wherein the subject is not a mouse and the vector expresses a disease antigen.
[0003] The present invention also relates to a pharmaceutical composition comprising a replication-defective murine cytomegalovirus (MCMV) vector suitable for inducing an antigen-specific immune response in a subject, wherein the vector expresses a disease antigen, and wherein the composition is formulated for administration to a non-mouse subject. In an embodiment, the vector has a disrupted immediate early 2 (ie2) gene, resulting in a replication defect of the vector in a non-mouse subject.
[0004] The present invention also relates to the use of a pharmaceutical composition for inducing an antigen-specific immune response to an expressed disease antigen in a non-mouse subject.
[0005] The present invention also relates to a method of inducing an antigen-specific immune response in a subject comprising administering a replication-defective murine cytomegalovirus (MCMV) vector, wherein the subject is not a mouse, and wherein the vector expresses a disease antigen.
[0006] The present invention also relates to a method for inducing an antigen-specific immune response in a subject, comprising administering a pharmaceutical composition comprising a replication-defective murine cytomegalovirus (MCMV) vector, wherein the vector expresses a disease antigen, and wherein the composition is formulated for administration to a non-mouse subject, preferably a non-mouse subject including a human or veterinary acceptable carrier, excipient, solvent and / or adjuvant. Background Art
[0007] The severe COVID-19 global pandemic has claimed millions of lives and caused severe economic disruptions worldwide. Influenza pandemics have also caused global disruptions, such as the 1918 H1N1 Spanish flu, the 1968 H3N2 flu, and the 2009 H1N1dpm09 swine flu, and have led to the rapid spread of this respiratory disease around the world. In addition to these influenza pandemics, seasonal influenza epidemics often cause increased morbidity and mortality during the cold season. Both influenza viruses (IAV) and SARSCoV-2 can cause mild to severe respiratory illness and pose a particular threat to high-risk populations, such as the elderly or those with pre-existing medical conditions. Both respiratory viruses rely on viral surface proteins for attachment and entry into host cells. In the case of IAV, the viral hemagglutinin (HA) is the major surface glycoprotein required for cell entry. Similarly, SARS-CoV-2 uses the spike protein (S) to bind to its cellular receptor ACE2 and drive membrane fusion upon viral entry. Therefore, SARS-CoV-2 S and IAV HA are the main antigenic targets for vaccine formulations against these viruses.
[0008] There are currently more than 200 vaccine projects targeting SARS-CoV-2 using formulations containing viral proteins, viral vector vaccines, and mRNA vaccines. Some of these vaccines have been approved for use in humans or are in advanced clinical trials with promising results.
[0009] However, all candidates present safety concerns due to side effects such as fever, fatigue, and headache, and most vaccines (or vaccine candidates) require a prime / boost vaccination regimen every few weeks, which raises distribution logistics and compliance issues. Although mRNA vaccines show great promise in the context of the COVID-19 pandemic, experience with their use in clinical settings remains limited.
[0010] Vaccines against influenza target the strains predicted to circulate each upcoming flu season and are especially recommended for high-risk groups, such as children, the elderly, and immunocompromised individuals. While influenza vaccines are available, their effectiveness is approximately 19-60%, depending on the flu season.
[0011] WO 2011 / 093858 discloses that a recombinant replication-deficient murine cytomegalovirus (MCMV) induces a T cell-based immune response in a subject against a heterologous antigen expressed by CMV.
[0012] Klyushnenkova et al. disclosed that a mouse CMV-based vaccine expressing human prostate-specific antigen induced an antitumor immune response (Elena et al., "A Cytomegalovirus-based Vaccine Expressing a Single Tumor-specific CD8(+)T-cell Epitope Delays Tumor Growth in a Murine Model of Prostate Cancer", Journal of Immunotherapy, 1 June 2012). The antitumor effect was demonstrated in a humanized double transgenic mouse model. The ie2 gene can be deleted or mutated without affecting the replication of the virus in vivo.
[0013] Mohr et al. disclosed that a spread-deficient murine CMV lacking the essential gene M94 can induce robust CD4+ and CD8+ T cell responses and neutralizing antibody responses (Mohr et al., "A Spread-Deficient Cytomegalovirus for Assessment of First-Target Cells in Vaccination", Journal of Virology, 1 August 2010). MCMV-ΔM94 does not revert to a replication-competent virus in mice.
[0014] The availability of effective vaccines and vaccine vectors remains a serious medical need. Viral vector-based vaccines, such as those based on adenovirus, provide robust immune protection and are part of the vaccine portfolio against the current COVID-19 pandemic, but cannot be effectively reused against other targets. This limitation is due to vector-specific neutralizing antibodies, which are generated during the initial vaccination. Therefore, on the one hand, this limits the delivery of antigens to cells upon repeated administration. On the other hand, it promotes the induction of recall immune responses to adenoviral antigens at the expense of immune sensitization.
[0015] Therefore, there is an urgent need for other viral vectors that can elicit robust immune responses and protection, not only for COVID-19 and influenza, but also for other infectious diseases caused by viruses, bacteria and / or parasites. Specifically, vectors are needed that cause minimal or no disease manifestations during administration, but induce robust and long-lasting immunity to the encoded antigen. Summary of the invention
[0016] In view of the prior art, the technical problem underlying the present invention is to provide alternative and / or improved means for inducing an antigen-specific immune response in a subject.
[0017] This problem is solved by the features of the independent claim. Preferred embodiments of the invention are provided by the dependent claims.
[0018] Thus, the present invention relates to the use of a replication-defective murine cytomegalovirus (MCMV) vector for inducing an antigen-specific immune response in a subject, wherein the subject is not a mouse, and wherein the vector expresses a disease antigen.
[0019] The present invention also relates to the use of a replication-defective murine cytomegalovirus (MCMV) vector as a medicament for inducing an antigen-specific immune response in a subject, such as for inducing immunity to the antigen, wherein the subject is not a mouse and wherein the vector expresses a disease antigen.
[0020] The present invention also relates to a pharmaceutical composition comprising a replication-defective murine cytomegalovirus (MCMV) vector suitable for inducing an antigen-specific immune response in a subject, wherein the vector expresses a disease antigen, and wherein the composition is formulated for administration to a non-mouse subject.
[0021] Another aspect relates to a method of inducing an antigen-specific immune response in a subject comprising administering a replication-defective murine cytomegalovirus (MCMV) vector, wherein the subject is not a mouse, and wherein the vector expresses a disease antigen.
[0022] Another aspect relates to a method of inducing an antigen-specific immune response in a subject, comprising administering a pharmaceutical composition comprising a replication-defective murine cytomegalovirus (MCMV) vector, wherein the vector expresses a disease antigen, and wherein the composition is formulated for administration to a non-mouse subject, preferably comprising a human or veterinary acceptable carrier, excipient, solvent and / or adjuvant.
[0023] In an embodiment, the vector has a disrupted immediate early 2 (ie2) gene, rendering the vector replication-defective in a non-mouse subject.
[0024] Vaccines based on viral vectors are widely used in experimental and clinical conditions. On the one hand, many countries have approved a variety of adenovirus-based vectors for clinical use against COVID-19, including Vaxzevria, COVID-19 vaccine Jannsen, Convidecia or Sputnik-V, either as a single injection or as a prime-boost formulation. Examples of other vaccine vectors with limited use in veterinary or human medicine include Newcastle disease virus (NDV), vesicular stomatitis virus (VSV) or modified vaccinia Ankara (MVA) vectors. These viruses have been tested as vectors for MERS, Ebola, rabies, influenza, West Nile virus and many other antigens under experimental conditions. They show reliable biosafety, are able to elicit T cell responses and provide immune protection.
[0025] CMV vectors have been shown to provide robust and long-lasting immunogenicity following immunization, whether based on cellular or humoral immunity. Rhesus macaque CMV vectors are used in rhesus macaque models of tuberculosis, HIV, or malaria infection. In mouse infection models, murine (mouse) CMV vectors have been used against influenza, tumors, herpes simplex, tuberculosis, and Ebola. Human CMV vectors are currently in Phase I clinical trials.
[0026] Most non-CMV-based models typically provide cellular and humoral immune responses that wane over time. CMV vectors are uniquely capable of eliciting lifelong protective immunity due to their ability to maintain their latent genome in an episomal form within the cells of the vaccinated host and to re-stimulate the immune system over time.
[0027] Adenoviruses have a limited ability to persist in host cells for an extended period of time, and therefore induce responses that last slightly longer. However, immunity against adenoviral vectors limits their ability to be used repeatedly against independent infection targets. In addition, natural immunity against adenoviral vectors in humans limits their use. Therefore, CMV-based vectors have distinct advantages over non-CMV vectors.
[0028] Among CMV vectors, many studies have focused on the properties of MCMV vectors in mouse models, but to the best of the inventors' knowledge, their functionality has not yet been tested in non-natural host species.
[0029] Although WO2011 / 093858 teaches the generation of a long-term, repeatedly stimulated immune response to a heterologous antigen in a subject by administering a recombinant, replication-deficient cytomegalovirus expressing a heterologous antigen, no experiments were conducted using MCMV in human subjects. In contrast, Example 6 of the present application discloses the use of human replication-deficient CMV expressing a tumor antigen in a Phase I clinical trial, for example, in patients with stage 4 melanoma. To the best of the inventors' knowledge, there is no prior disclosure in the prior art that teaches the administration of murine CMV in a non-murine host (preferably a human) to induce an antigen-specific immune response in the host to a (transgenic expressed) disease antigen.
[0030] Similarly, many studies have shown that rhesus macaque CMV (RhCMV) vaccine vectors are effective in the natural host species, rhesus macaques. Vectors based on this type of approach require the use of the human CMV genome (HCMV) as a vaccine vector. Such vectors exist and are in early clinical trials. However, these vectors generally have several limitations:
[0031] HCMV is a pathogenic virus that can cause harm to human hosts, and the use of HCMV-based vectors carries an inherent risk of pathogenicity. Such risks can be mitigated by genetically modifying the virus, including attenuating the growth of HCMV vectors by gene deletion or insertion of sequences that disrupt essential viral proteins through recombinant DNA methods.
[0032] In contrast, the vectors of the present invention are inherently safer in human cells because MCMV is poorly suited to growth in human cells.
[0033] The exquisite adaptation of CMV to its natural host species results in a strongly suppressed immune response, thereby inhibiting the adjuvant potential of CMV vectors. Our vector system activates the innate immune response.
[0034] Natural immunity to HCMV may interfere with the ability of the HCMV vector to express antigens in the host. HCMV is ubiquitous and most human populations are seropositive for the virus. MCMV does not naturally infect humans, so this concern is irrelevant.
[0035] The possibility of homologous recombination between HCMV vaccine vectors and naturally occurring wild-type HCMV is stronger than that between MCMV vectors, and the genetic homology between MCMV vectors and HCMV is relatively moderate.
[0036] There is very limited evidence for the use of MCMV vectors in heterologous species. A previous publication (Wang et al., J Virol 2003; 77(13): 7182-92) showed that infection of human dendritic cells with MCMV vectors encoding the gp120 gene of HIV elicited a cellular immune response to the antigen in vitro. However, the study was based on a vector that was replication-competent and expressed the ie2 gene and was present in the human retinal pigment epithelium. In addition, the authors of the study did not test the ability of their vector to induce an immune response and immune protection in an in vivo system.
[0037] Therefore, in an embodiment, the present invention utilizes a replication-deficient MCMV vector (preferably ie2-deficient MCMV) as a vaccine vector that is replication-restricted in all tested human cell types but fully replication-competent in mouse cells. The vector is capable of expressing antigens in human cells and is immunogenic and protective in animal models that are not the natural host species of MCMV.
[0038] To the best of the inventors' knowledge, there are currently no publications on vaccine vectors based on the MCMV gene platform that are safe and widely used for veterinary and human medical applications. In the Examples, we demonstrated that the ie2 gene (known to be dispensable for MCMV growth in mouse cells) is essential for MCMV replication in human retinal antigen epithelial (RPE) cells, that MCMV lacking ie2 can still express genes and antigens in human cells, particularly in professional antigen-presenting cells, which allows antigen-specific T lymphocytes to recognize antigens, and that such vectors induce humoral immune responses and protection in hosts that have not been vaccinated with murine vaccines, with typical examples being vaccination of hamsters and challenge with SARS-CoV-2.
[0039] Various aspects of the present invention are unified in, benefit from, are based upon and / or relate to a common and surprising discovery that replication-defective murine cytomegalovirus (MCMV) vectors can be effectively used to induce antigen-specific immune responses in subjects that are not natural hosts of the viral vector.
[0040] The use of viral vectors in non-natural hosts represents an unexpected discovery of the present invention. To the best of the inventor's knowledge, the art has neither disclosed nor suggested the use of, for example, mouse CMV vectors in human subjects. Therefore, the medical use of the present invention represents a new method for providing safe and effective viral vectors in human and veterinary settings.
[0041] Human CMV viral vectors are referred to as vaccine vectors for expressing disease antigens in human subjects. The present invention is different from using vectors in their natural hosts by selecting non-human CMV vectors for administration in, for example, humans. The replication defect of the vector of the present invention is effectively administered in a subject, but does not necessarily hinder the replication of the vector in a mouse host. In other words, the vector of the present invention can be replicated in the natural host of the vector and therefore produced in large quantities, but will not be replicated in, for example, a human subject.
[0042] This replication-deficient murine cytomegalovirus vector is able to induce antigen-specific immune responses against infectious diseases or cancer in the host without replicating and, therefore, spreading within the host. This advantage meets an urgent medical need for highly effective vaccines. So far, vaccines based on viral vectors, such as those based on adenovirus, have provided robust immune protection and formed part of vaccine combinations against the current COVID-19 pandemic, but cannot be effectively reused against other targets. This limitation is due to vector-specific neutralizing antibodies, which are elicited during the initial vaccination. This unwanted immune response limits the delivery of antigens to cells after repeated dosing and promotes the induction of recall immune responses against adenoviral antigens at the expense of immune sensitization.
[0043] One advantage of the present invention is based on the surprising discovery that the contemplated viral vectors are replication-defective in non-mouse subjects and therefore do not spread in the host nor induce immune sensitization in the host cultured by the viral vector itself. At the same time, robust immune protection against a variety of infectious diseases and cancers can be obtained, depending on the choice of disease antigens.
[0044] In addition, from Fig.16 ,in particular Fig.16 C and Fig.16 D. The pVNT50 values obtained for individual hamsters 4 weeks or 3 months after vaccination against different SARS-CoV-2 variants indicate that the antibody titers obtained increased over time. This represents a beneficial and unexpected result, suggesting that antigen-specific immunity may not wane or decrease over time after administration of vaccine mCMV vectors, thereby reducing the need for booster immunization, such as in the case of mRNA vaccines.
[0045] In an embodiment, the vector described herein is characterized in that the open reading frame of the disease antigen is expressed by the immediate early MCMV promoter.
[0046] In embodiments, the open reading frame of the disease antigen is expressed by a constitutive promoter or an inducible promoter. In embodiments, the constitutive promoter and the inducible promoter can be an exogenous promoter operably linked to the open reading frame of the disease antigen, which drives the expression of the disease antigen in the host.
[0047] Constitutive promoters known in the art include, but are not limited to, CAG promoter, CMV early enhancer / short variant of chicken β-actin (sCAG) promoter, hCMV promoter, phosphoglycerate kinase (PGK) promoter, human synapsin promoter (hSYN), SV40 early (SV40e) promoter region, promoter contained in the 3' long terminal repeat (LTR) of Rous sarcoma virus (RSV), promoter of E1A or major late promoter (MLP) gene of adenovirus (Ad), cytomegalovirus (CMV) early promoter, herpes simplex virus (HSV) thymidine kinase (TK) promoter, baculovirus IE1 promoter, elongation factor 1α (EF1) promoter, ubiquitin (Ubc) promoter, albumin promoter, small Regulatory sequences of the mouse metallothionein-L promoter and transcription control region, ubiquitous promoters (HPRT, vimentin, α-actin, tubulin, etc.), intermediate filament (desmin, neurofilament, keratin, GFAP, etc.) promoters, therapeutic gene (MDR, CFTR or factor VIII type, etc.) promoters, pathogenesis or disease-related promoters, and promoters that show tissue specificity and have been used in transgenic animals, such as the elastase I gene control region active in pancreatic acinar cells; the insulin gene control region active in pancreatic β cells, the immunoglobulin gene control region active in lymphocytes, the mouse mammary tumor virus control region active in testis, breast, lymph and mast cells; the albumin gene, ApoE2, which are active in the liver. AI and Apo AII control regions, alpha-fetoprotein gene control regions active in the liver, alpha1-antitrypsin gene control regions active in the liver, beta-globin gene control regions active in bone marrow cells, myelin basic protein gene control regions active in oligodendrocytes of the brain, myosin light chain-2 gene control regions active in skeletal muscle, gonadotropin-releasing hormone gene control regions active in the hypothalamus, pyruvate kinase promoter, villin promoter, fatty acid-binding enteric protein promoter, smooth muscle cell alpha-actin promoter, etc. In addition, these expression sequences can be modified by adding enhancers or regulatory sequences, etc. In an embodiment, the vector described herein is characterized in that an open reading frame of a disease antigen is inserted into the vector to replace any non-essential viral genomic sequence.
[0048] In the context of the present invention, an inducible promoter refers to a regulatable promoter that is active only in a specific tissue, a specific tumor or after treatment, in response to a specific stimulus (including, for example, an exogenous stimulus).
[0049] In an embodiment, the inducible promoter can be a tetracycline or doxycycline inducible promoter. The inducible promoter can also be a tissue-specific promoter, including but not limited to:
[0050] Leukocyte specificity: CD11a promoter, CD11b promoter, CD18 promoter,
[0051] Erythrocyte-specific: β-globin promoter / LCR,
[0052] B lymphoma specific: immunoglobulin promoter,
[0053] Hepatocyte specificity: PEPCK promoter, albumin promoter, hAAT promoter,
[0054] Breast cancer specific: MMTV-LTR, WAP promoter, β-casein,
[0055] Bronchial and alveolar epithelial specificity: SPC promoter, SP-A and SP-B,
[0056] Undifferentiated myogenic cell specific: MCK promoter,
[0057] Myoblast-specific: VLC1 promoter,
[0058] Lymphocyte specificity: HIV-LTR.
[0059] Inducible promoters can also be response elements, including but not limited to Tat / Rev response elements and Tat inducible elements of CD4 positive cells. Inducible promoters can also be cancer-specific promoters, such as CEA promoters for colon cancer and lung cancer, AFP promoters for hepatocellular carcinoma, SLPI promoters for cancer, thyrosinase promoters for melanoma, c-erbB2 promoters for breast cancer, pancreatic cancer, gastric cancer and lung cancer. Inducible promoters can also refer to therapeutic inducible promoters, including but not limited to Erg-1 promoters for radiation tumors, Grp78 promoters for hypoxic acidic tumor tissues, MDR1 promoters for chemotherapy treatment of tumors, and HSP70 promoters for high temperature treatment of tumors. Suitable promoters for driving disease antigen expression can be determined by those skilled in the art according to, for example, the purpose of delivering the expected MCMV to the host, the host itself and the delivery route.
[0060] In embodiments, the vectors described herein comprise a disrupted immediate early 2 (ie2) gene, rendering the vector replication-defective in a non-mouse subject.
[0061] In one embodiment, the ie2 gene sequence is according to SEQ ID NO: 1:
[0062] ccgtgctgattcatatgccatatgagtgtattagggggctttccgcttgggaaattgggtaaaaagtccccgtattactcacatagggggcgtttggctttgcaaattaggggatttcagtgcatttggcattaaaaactattggttctagtcataaaacgggcggagttAACCATATAAAAGCTGTCCCCCATGCCATTCGA GCCCAGAGCAGGACGGA CCGCGGCTCGATACGACCCTATCTACGTT aacgagcgggtgaacggagccccccaggccgggtaaggttgcattgggctcggctatgggacggggatttggcccggtactttaatatgggtggggtct In one embodiment, deletion of the uppercase sequence (SEQ ID NO: 3) results in IE2 dysfunction.
[0063] SEQ ID NO:3:
[0064] AACCATATAAAAGCTGTCCCCCATGCCATTCGA GCCCAGAGCAGGA CGGACCGCGGCTCGATACGAC CCTATCTACGTT
[0065] The underlined sequence is exon 1 of the ie2 gene, according to SEQ ID NO:4:
[0066] GCCCAGAGCAGGACGGACCGCGGCTCGATACGACCCTATCTACGTT The deletion of SEQ ID NO: 3 represents only one example of producing a functionally disrupted IE2. A person skilled in the art can produce a disrupted ie2 gene according to various methods known to those skilled in the art.
[0067] This mouse ie2 is not necessary for the growth and latency of MCMV vectors in mice, but is essential for the growth of non-mouse subjects. In an embodiment, the disrupted ie2 gene causes replication defect in humans or other non-mouse subjects due to its replication defect or incomplete replication in these subjects. This surprising and beneficial discovery makes the vectors described herein suitable for inducing antigen-specific immune responses in non-mouse subjects without triggering immune sensitization to the viral vector.
[0068] In an embodiment, the ie2 gene is disrupted by deleting the ie2 gene or a portion thereof.
[0069] In a preferred embodiment, the ie2 gene is disrupted by deleting the TATA box or deleting the ie2 open reading frame or a portion thereof.
[0070] The TATA box of the ie2 gene is shown in bold capital letters in SEQ ID NOs: 1 and 3.
[0071] In other embodiments, replication defective MCMV includes the gene disruption that causes incomplete or defective replication, rather than ie2 disruption or the gene disruption except ie2 disruption. Expected disrupted gene can be any one or more genes of the conservative cell function targeted in MCMV. The mutation of these genes causes only duplication in mouse cells, and replicates incompetence or replication defect in non-mouse subjects. These genes include but are not limited to the viral genes of targeted apoptosis molecules, such as M36, M38.5, m41, affect the gene of promyelocytic leukemia (PML) related nuclear body (such as IE1) or interferon signal transduction (such as M35, M27). Those skilled in the art can identify this type of gene according to the general technology of the art, and identify the replication defect caused by this type of gene disruption.
[0072] In an embodiment, an open reading frame for a disease antigen is inserted into the vector to replace the ie2 open reading frame or a portion thereof.
[0073] In other embodiments, the disease antigen can be inserted into any position of the viral vector, wherein the disease antigen can be under the control of an operably linked sequence, preferably a promoter that drives the expression of the disease antigen.
[0074] In some embodiments, the operably linked sequence is a promoter, including an inducible promoter. In embodiments, a reading frame for a disease antigen driven by the immediate early MCMV promoter is inserted into the vector to replace any non-essential viral genomic sequences.
[0075] In one embodiment, the subject is a human. In some embodiments, the subject is a non-human animal. Human medical and veterinary applications are contemplated.
[0076] In embodiments, the immune response comprises a neutralizing antibody response or a T cell response to a disease antigen.
[0077] In embodiments, the immune response includes sensitizing, maintaining and / or enhancing the subject's immune system. In embodiments, sensitization, maintenance and enhancement of the immune system may occur in a subject upon single or multiple delivery of a viral vector to the subject.
[0078] In embodiments, disease antigens include antigens or fragments thereof of pathogenic viruses, bacteria, parasites and / or cancer cells.
[0079] In embodiments, viral antigens include, but are not limited to, antigens from a coronavirus, influenza virus, herpes virus, polyoma virus, papilloma virus, orthomyxovirus, paramyxovirus, picornavirus, parvovirus, reovirus, rhabdovirus, togavirus, African swine fever, adenovirus, coxsackievirus, arenavirus, retrovirus, alphavirus, pestivirus, flavivirus, or arbovirus.
[0080] In an embodiment, the viral antigen is the spike, envelope, membrane, nucleoprotein, or any portion thereof, of SARS-CoV-2.
[0081] In one embodiment, the nucleic acid sequence encoding the SARS-CoV-2 spike protein is according to SEQ ID NO: 2:
[0082]
[0083] In embodiments, bacterial antigens include, but are not limited to, antigens from mycobacterium, Listeria, Chlamydia, Rickettsia, Yersinia, Helicobacter, Legionella, Streptococcus, Staphylococcus, Neisseria, or Salmonella.
[0084] In embodiments, parasite antigens include, but are not limited to, antigens from Plasmodium or Trypanosoma.
[0085] Another aspect of the invention relates to a pharmaceutical composition comprising a replication-defective murine cytomegalovirus (MCMV) vector suitable for inducing an antigen-specific immune response in a subject, wherein the vector expresses a disease antigen, and wherein the composition is formulated for administration to a non-mouse subject.
[0086] For example, the composition can be formulated for administration in non-mouse subjects by determining appropriate administration form, dosage, volume and preparation. The technician can assess any given composition form for administration and determine whether it is suitable for or used for administration in mice and / or other subjects. For example, compared with using in mice, larger dosage, larger volume, formulation type (such as tablet, injection or other forms), formulation packaging and / or other formulation aspects will clearly indicate, for example, use in humans.
[0087] Another aspect of the invention relates to a pharmaceutical composition comprising a replication-defective murine cytomegalovirus (MCMV) vector, wherein the vector has a disrupted immediate early 2 (ie2) gene, rendering the vector replication-defective in a non-mouse subject, wherein the vector expresses a disease antigen, and wherein the composition is formulated for administration to a non-mouse subject.
[0088] Such pharmaceutical compositions can induce antigen-specific immune responses for, for example, infectious diseases or cancers in a host without spreading in the host. This increases the safety level of the composition for administration to humans or non-human animals. The pharmaceutical composition can be formulated as a vaccine for administration. Advantageously, this vaccine comprises a viral vector comprising replication-deficient MCMV, which itself does not induce or induces an unwanted immune response to a low degree. This unwanted immune response limits the delivery of antigens to cells during repeated administration, and is conducive to inducing a recall immune response to viral vector antigens at the expense of immune sensitization.
[0089] Based on the surprising finding that vaccines containing the intended viral vectors are replication-deficient in non-mouse subjects, one advantage is that the intended viral vectors will not spread in the host and will not cause immune sensitization in the host cultured by the viral vector itself. At the same time, depending on the choice of disease antigens, robust immune protection against a variety of infectious diseases and cancers can be obtained.
[0090] In an embodiment of the present invention, the vaccine according to the present invention is not only capable of establishing a lifelong expansive CD8+ T cell response, but is also capable of inducing a B cell-based humoral response, thereby preventing the spread of the virus through the extracellular fluid. It has been demonstrated that vaccination with the intended vaccine can induce a neutralizing humoral immune response against pandemic viruses (such as influenza virus, SARS-CoV-2). The humoral immunity induced by the intended vaccination can better prevent pandemic viruses, such as influenza virus, SARS-CoV-2, as well as the robust cellular immunity induced by the intended vaccination.
[0091] Another advantage of the expected vaccine is to provide long-term immunity. In embodiments, the level of neutralizing antibodies can increase over time, such that the level of class-switched isotypes gradually increases at later time points after vaccination, which may be accompanied by an increase in affinity. Without being bound by theory, due to the expected replication defects of the viral vector, continued re-stimulation of antigen-specific B cells by sparse antigen expression during the latent period represents another potential benefit of a highly effective vaccine.
[0092] In an embodiment, the pharmaceutical composition is a vaccine, preferably formulated for single-dose administration.
[0093] Single-dose administration may be advantageous, for example, in settings or regions where there is a significant lack or limitation of facilities to manufacture viral vector vaccines, or where cold chain storage capacity is limited. Single-dose vaccination could help accelerate pandemic control because vaccine coverage could be doubled using a single-dose vaccine rather than a two-dose or multi-dose regimen. Single-dose vaccination could also help mitigate adverse events, such as fever, headache, chills, and fatigue, which have been reported to occur at higher rates with second or more doses of the vaccine.
[0094] Based on the findings shown herein, long-term immune protection, including neutralizing antibody responses, can be achieved with a single dose of vaccination, thereby eliminating the need for booster vaccinations.
[0095] In an embodiment, the pharmaceutical composition also includes a human or veterinary acceptable carrier, excipient, solvent and / or adjuvant. Adjuvants and suitable formulations are known to the skilled person and can be selected accordingly to produce a composition suitable for administration in any given targeted subject. In an embodiment, the pharmaceutical composition is used to induce an antigen-specific immune response in a non-mouse subject affected by an expressed disease antigen.
[0096] Another aspect relates to a method of inducing an antigen-specific immune response in a subject comprising administering a replication-defective murine cytomegalovirus (MCMV) vector, wherein the subject is not a mouse, and wherein the vector expresses a disease antigen.
[0097] In an embodiment, the vector has a disrupted immediate early 2 (ie2) gene, rendering the vector replication defective in a non-mouse (preferably human) subject.
[0098] In an embodiment, an open reading frame for a disease antigen is inserted into the vector to replace the ie2 open reading frame or a portion thereof.
[0099] Another aspect relates to a method of inducing an antigen-specific immune response in a subject, comprising administering a pharmaceutical composition comprising a replication-defective murine cytomegalovirus (MCMV) vector, wherein the vector expresses a disease antigen, and wherein the composition is formulated for administration to a non-mouse subject, preferably comprising a human or veterinary acceptable carrier, excipient, solvent and / or adjuvant.
[0100] In an embodiment, the vector has a disrupted immediate early 2 (ie2) gene, rendering the vector replication defective in a non-mouse (preferably human) subject.
[0101] In an embodiment, the pharmaceutical composition is a vaccine, preferably formulated for single-dose administration.
[0102] Embodiments describing the medical use of the present invention can be used to describe pharmaceutical compositions comprising vectors of the present invention and methods for inducing antigen-specific immune responses in subjects, and vice versa. This is also suitable for describing any embodiment of pharmaceutical compositions and methods for inducing antigen-specific immune responses in subjects. The present invention is unified by novel and beneficial replication-deficient murine cytomegalovirus (MCMV) vectors for inducing antigen-specific immune responses in non-mouse subjects, so the relevant features of one aspect described herein can be used to describe any given aspect of the present invention in a manner consistent with the understanding of those skilled in the art.
[0103] Detailed description of the invention
[0104] All citations in the patent and non-patent literature are hereby incorporated by reference in their entirety.
[0105] The present invention relates to the use of a replication-deficient mouse cytomegalovirus vector for inducing an antigen-specific immune response in a subject, wherein the subject is not a mouse subject, and wherein the vector expresses a disease antigen. The present invention also relates to a pharmaceutical composition comprising a replication-deficient mouse cytomegalovirus vector, wherein the vector preferably has a disrupted immediate early 2 (ie2) gene, resulting in the vector being replication-deficient in a non-mouse subject, wherein the vector expresses a disease antigen, and wherein the composition is formulated for administration to a non-mouse subject. The present invention also relates to the use of a pharmaceutical composition for inducing an antigen-specific immune response to an expressed disease antigen in a non-mouse subject.
[0106] In embodiments, the subject is not a murine subject. In embodiments, the vector is replication defective in a non-murine subject. In embodiments, the composition is formulated for administration to a non-murine subject. In embodiments, any reference to "non-mouse" may also refer to "non-murine".
[0107] Replication-deficient murine cytomegalovirus (MCMV) vectors are used to induce antigen-specific immune responses in subjects. The term "replication-deficient" in the context of the MCMV vectors described herein should refer to replication inability or complete inability to spread beyond primary non-murine host cells, preferably beyond mouse cells. Replication-deficient may also refer to undetectable replication of the virus in the host.
[0108] In embodiments, the replication-defective MCMV vectors used herein can establish latency, thereby providing repeated stimulation of the immune system, but are unable to produce infectious viral particles.
[0109] In an embodiment, replication defective MCMV comprises the gene disruption that causes replication incompetence or defect.The envisioned disrupted gene can be one or more genes of the conservative cell function of the target in MCMV.The mutation of these genes causes replication only in mouse cells, and replication incompetence or defect in non-mouse subjects.These genes include but are not limited to the viral genes of the targeted apoptosis molecules, such as M36, M38.5, m41, affect the gene of the relevant nuclear body (such as IE1) of promyelocytic leukemia (PML) or interferon signaling (such as M35, M27) or immediate early 2 (ie2).Those skilled in the art understand this type of gene, and can identify the replication defect caused by this type of gene disruption according to this area.
[0110] In one embodiment, the vector used herein has a disrupted immediate early 2 (ie2) gene, rendering the vector replication defective in a non-mouse subject. In an embodiment, the ie2 gene is disrupted by deleting the ie2 gene or a portion thereof.
[0111] As used herein, immediate early 2 (ie2), UniProtKB-P24909, refers to the murine cytomegalovirus alpha (immediate early) gene product, which is a protein related to the human cytomegalovirus US22 protein family. This murine ie2 is dispensable for the growth and latency of MCMV vectors in mice, but is essential for growth in non-murine subjects.
[0112] In embodiments, the disrupted ie2 results in replication defect in human or other non-murine cells due to its replication anergy or inability to replicate in these subjects. In other embodiments, the replication-defective MCMV vector as used herein comprises multiple inactivated essential genes required for the production of infectious viral particles.
[0113] As used herein, "disrupted ie2 gene" refers to a dysfunctional ie2 gene, which therefore encodes a functionally defective IE2 protein or does not encode any dysfunctional or functional IE2 protein. The destruction of ie2 can be achieved by methods known in the art. In an embodiment, the ie2 gene can be destroyed by directly inserting or deleting or replacing one or more nucleotides in the open reading frame of the ie2 gene. In an embodiment, the ie2 gene can be inactivated by inactivating an operably linked sequence of the ie2 gene, preferably a promoter that drives ie2 gene expression or other epigenetic modifications of the ie2 gene.
[0114] "Operably linked" shall mean that a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Typically, operably linked DNA sequences are contiguous and, where necessary to link two protein coding regions, in the same reading frame.
[0115] As used herein, the term "deletion" shall refer to the removal of a DNA sequence, with the regions on both sides of the removed sequence being joined together.
[0116] In an embodiment, the ie2 gene is disrupted by deleting the TATA box or deleting the ie2 open reading frame or a portion thereof.
[0117] As used herein, "open reading frame (ORF)" refers to a series of nucleotide triplets (codons) encoding amino acids without any internal stop codons. These sequences are usually translatable into peptides. The term "a portion of the ie2 open reading frame" should refer to any nucleotide or nucleotide sequence in the ie2 open reading frame whose deletion or modification leads to ie2 gene destruction or encoding dysfunctional IE2 protein or ie2 gene silencing.
[0118] As used herein, "TATA box" shall refer to a DNA sequence located in the core promoter region of a gene. The TATA box is a non-coding DNA sequence comprising a common sequence characterized by repeated T and A base pairs. Based on the sequence and mechanism of the TATA box, mutations such as insertions, deletions, and point mutations of the common sequence can result in phenotypic changes. In an embodiment, the deletion of the TATA box results in the destruction of the IE2 gene or the IE2 protein encoding dysfunctional or the gene silencing of IE2.
[0119] As used herein, the term "virus" shall have its ordinary meaning in the art. A virus consists essentially of a core of a single nucleic acid, surrounded by a protein coat (capsid), and has the ability to replicate only within living cells. "Viral replication" is the production of additional viral particles by the occurrence of at least one viral life cycle. A virus may disrupt the normal function of a host cell, causing the cell to behave in a manner determined by the virus.
[0120] As used herein, "cytomegalovirus (CMV)" refers to a member of the beta subclass of the herpesvirus family. CMV is a relatively large (containing a 230 kilobase genome) double-stranded DNA virus with host range-specific variants, such as MCMV (murine CMV) and HCMV (human CMV).
[0121] The term "murine cytomegalovirus (MCMV)" refers to a herpesvirus of the subfamily betaherpesvirus. It is a double-stranded enveloped DNA virus with host specificity for mice. Murine cytomegalovirus (MCMV) was first described in 1954 and has been used to model human cytomegalovirus (HCMV) disease in mice. MCMV is a natural pathogen of mice and is present in wild mouse populations. MCMV can be determined by sequence analysis. For example, the complete DNA sequence of the Smith strain of murine cytomegalovirus (MCMV) was determined from virion DNA using a whole genome shotgun approach (Rawlinson, J Virol 1996, Dec; 70 (12): 8833-49). The total G+C content of the genome is 58.7%, consisting of 230,278 bp, and arranged as a single unique sequence with short (31-bp) terminal direct repeats and several short internal repeats. Sequence variations may occur and can be detected by technicians.
[0122] The term "vector" refers to any exogenous DNA or RNA vector that can be used to transfer exogenous DNA to a host cell, for example, for replication and / or appropriate expression of the exogenous DNA by the host cell. A vector nucleic acid molecule of a specific sequence can be incorporated into a vector, which is then introduced into a host cell, thereby producing a transformed host cell. The vector can be a viral vector, such as a CMV vector. The viral vector can be constructed from a wild-type or attenuated virus, including a replication-defective virus.
[0123] In embodiments, replication-deficient MCMV vectors are used to carry foreign DNA to non-murine host cells so that the host cells express the foreign DNA. In embodiments, the vectors described herein express disease antigens, wherein the disease antigens are expressed in host cells.
[0124] The term "antigen" shall refer to a substance capable of stimulating, for example, the production of antibodies or T cell responses in a mammal, including compositions that are injected or absorbed into a mammal. Antigens react with products of specific humoral or cellular immunity, including products induced by heterologous immunogens. The term "antigen" includes all related antigenic epitopes.
[0125] As used herein, the term "disease antigen" is interchangeable with "pathogenic antigen" or "disease-associated antigen". A disease antigen may be expressed concurrently with a specific disease process, wherein antigen expression is associated with or predicts the development of the disease. Disease antigens include, for example, oncogenes associated with certain types of cancer. Disease antigens may be antigens recognized by T cells or B cells. Some disease antigens may also be tissue specific. Tissue-specific antigens are expressed in a limited number of tissues.
[0126] In embodiments, the disease antigen is a viral antigen, including but not limited to antigens of coronavirus, influenza virus, herpes virus, polyoma virus, papilloma virus, orthomyxovirus, paramyxovirus, picornavirus, parvovirus, reovirus, rhabdovirus, togavirus, African swine fever, adenovirus, coxsackievirus, arenavirus, retrovirus, alphavirus, pestivirus, flavivirus, or arbovirus. In embodiments, the viral antigen is the spike, envelope, membrane, nucleoprotein, or any portion thereof, of SARS-CoV-2. In embodiments, the viral antigen is the hemagglutinin or neuraminidase of influenza virus.
[0127] In embodiments, the disease antigen is a bacterial antigen, including but not limited to antigens of Mycobacterium, Listeria, Chlamydia, Rickettsia, Yersinia, Helicobacter, Legionella, Streptococcus, Staphylococcus, Neisseria, or Salmonella.
[0128] In embodiments, the disease antigen is a parasite antigen, including but not limited to an antigen of Plasmodium or Trypanosoma.
[0129] In the context of a disease antigen according to the present invention, the term "any part thereof" refers to any fragment thereof that contains more than one amino acid and is capable of inducing the same immune response as the entire part of the antigen or is associated with a disease caused by the entire part of the disease antigen. It includes, for example, epitopes, also known as antigenic determinants of disease antigens, which are specific chemical groups or peptide sequences on a molecule that are antigenic, thereby eliciting a specific immune response. For example, an epitope can be a tumor-derived polypeptide that is expressed by a nucleic acid delivered to a cell by a recombinant defective MCMV vector (preferably in the form of a vaccine).
[0130] The term "any portion thereof" further refers to a portion of a polypeptide that exhibits at least one useful epitope. Thus, the phrase "any portion thereof" refers to all fragments of a polypeptide that retain an activity or a measurable portion of the activity of the polypeptide from which the fragment was derived. For example, the size of a fragment can range from a small polypeptide fragment capable of binding an epitope of an antibody molecule to a large polypeptide capable of participating in the characteristic induction or programming of phenotypic changes in a cell. An epitope is a region of a polypeptide capable of binding an immunoglobulin produced in response to contact with an antigen.
[0131] As used herein, the term "cancer" refers to a malignant tumor that has undergone a characteristic degenerative development, loss of differentiation, increased growth rate, invasion of surrounding tissues, and / or the ability to metastasize. As used herein, the term "tumor" is a neoplasm. The term includes solid tumors and hematological tumors.
[0132] Examples of hematological neoplasms include, but are not limited to, leukemias, including acute leukemias (e.g., acute lymphocytic leukemia, acute myeloid leukemia, acute myeloid leukemia, and granulocytic leukemia, promyelocytic leukemia, myelomonocytic leukemia, monocytic leukemia, and erythroleukemia), chronic leukemias (e.g., chronic myeloid leukemia and chronic lymphocytic leukemia), myelodysplastic syndrome and myelodysplasia, polycythemia vera, lymphomas (e.g., Hodgkin's disease, all forms of non-Hodgkin's lymphoma), multiple myeloma, Waldenstrom's macroglobulinemia, and heavy chain disease.
[0133] Examples of solid tumors, such as sarcomas and carcinomas, include, but are not limited to, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma and other sarcomas, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, pancreatic cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, Wilms' tumor, cervical cancer, testicular tumors, bladder cancer, melanoma, and CNS tumors (e.g., glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, meningioma, neuroblastoma, and retinoblastoma).
[0134] As used herein, the term "cancer cell antigen" shall refer to a tumor antigen capable of stimulating a tumor-specific T cell-defined immune response or antibodies against tumor cells. An immunogenic composition, such as a cancer vaccine, may include one or more tumor antigens.
[0135] In an embodiment, the disease antigen is expressed in a vector as described herein. In this case, the disease antigen can be placed in any position of the vector, wherein the disease antigen can be controlled by an operably linked sequence, preferably a promoter that drives the expression of the disease antigen. In some embodiments, the operably linked sequence is a promoter, including an inducible promoter. In an embodiment, the reading frame of the disease antigen driven by the immediate early MCMV promoter is inserted into the vector to replace any non-essential viral genome sequence.
[0136] The term "non-essential viral genomic sequence" shall refer to any viral gene that is not required for viral replication in a cell (preferably in a mouse cell, more preferably in a mouse cell), such as M34, ie1, ie2 or ie3. Non-essential genes in cells may play a role in the viral pathogenesis of the host. There are many techniques known in the art for identifying essential and non-essential viral genes. For example, RNA interference or inhibition (RNAi) has been used to identify essential and non-essential frog virus genes (Sample et al., 2007, Virology. 2007 Feb 20; 358 (2): 311-20; Whitley et al., 2011, Dev Comp Immunol. 2011 Sep; 35 (9): 937-48, Xie 2004 et al., Virus Res. 2014 Aug 30; 189 (): 214-25). For example, this method is to inhibit or knock down ORF expression at the mRNA level, and viral growth can be used to measure the necessity of the target ORF.
[0137] In an embodiment, a disease antigen is inserted into the vector to replace the ie2 open reading frame or a portion thereof. In an embodiment, the replication-deficient MCMV vector described herein can be generated by inserting a gene for a disease antigen into the position of the ie2 gene, i.e., replacing the start and stop codons of the ie2 ORF with the start and stop codons of the open reading frame of the disease antigen. For example, a replication-deficient MCMV vector expressing the SARS-CoV-2 spike can be generated by inserting the full-length spike ORF with the start and stop codons of the spike ORF.
[0138] In an embodiment, the disease antigen is a spike protein of a coronavirus, preferably a spike protein of SARS-CoV-2.
[0139] Coronaviruses are a group of related viruses that cause disease in mammals and birds. The scientific name for coronaviruses is Orthocoronavirus or Coronavirus. Coronaviruses belong to the family Coronavirinae. This family is divided into the subfamilies Coronavirus and Tolonavirinae, which are divided into six genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, Deltacoronavirus, Torovirus, and Odontovirus. Viruses in the Alphacoronavirus and Betacoronavirus genera primarily infect mammals, while the Gammacoronavirus genus infects birds, and members of the Deltacoronavirus genus have been found in both mammalian and avian hosts.
[0140] In humans, coronaviruses cause respiratory infections that can be mild, such as some common colds, or fatal, such as SARS, MERS, and COVID-19. Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome and a helical symmetric nucleocapsid. The genome size of coronaviruses is approximately 27 to 34 kilobases, making them the largest of the known RNA viruses.
[0141] Various human coronaviruses are known, such as but not limited to: human coronavirus OC43 (HCoV-OC43) of the β-CoV genus, human coronavirus HKU1 (HCoV-HKU1) of the β-CoV genus, human coronavirus 229E (HCoV-229E) of the α-CoV, human coronavirus NL63 (HCoV-NL63) of the α-CoV, Middle East respiratory syndrome-related coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
[0142] The risk factors for coronaviruses vary widely. Some can kill more than 30% of those they infect (such as MERS-CoV), while others are relatively harmless, such as the common cold. Coronaviruses can cause colds, with symptoms such as fever and sore throat, mainly in the winter and early spring. Coronaviruses can cause pneumonia (direct viral pneumonia or secondary bacterial pneumonia) and bronchitis (direct viral bronchitis or secondary bacterial bronchitis). Coronaviruses can also cause SARS.
[0143] Advances in nucleic acid sequencing technology (often referred to as next-generation sequencing, NGS) have provided large amounts of sequence data from a variety of biological samples and allowed the characterization of known and novel viral strains. Therefore, established methods can be used to identify coronavirus infections.
[0144] As used herein, the term "encoding" shall mean that if a polynucleotide in its native state or when manipulated by methods well known to those skilled in the art can be transcribed and / or translated to produce mRNA for and / or a polypeptide or a fragment thereof, then the polynucleotide is said to encode a polypeptide.
[0145] As used herein, the term "expression" shall mean the translation of a nucleic acid into a protein, such as the translation of an mRNA encoding a tumor antigen into a protein.
[0146] In embodiments, immune response includes neutralizing antibody response or T cell response to disease antigen.As used herein, the term "immune response" should refer to changes in immunity, such as immune system cells (such as B cells, T cells, macrophages, monocytes or polymorphonuclear cells) to the response of immunogenic agents in the subject.This response can be directed to a specific antigen ("antigen-specific response").In some embodiments, immune response is a T cell response, such as a CD4+ response or a CD8+ response.In another example, the response is a B cell response, and causes the production of specific antibodies for immunogenic agents.Immunity refers to a state in which a protective response can be produced after exposure to an immunogenic agent.Protective response can be antibody-mediated or immune cell-mediated, and can be directed to specific pathogens or tumor antigens.Immunity can be actively obtained (e.g., by exposure to immunogenic agents in nature or pharmaceutical compositions) or passively obtained (e.g., by administering antibodies or in vitro stimulated and amplified T cells).
[0147] In embodiments, the immune response comprises long-term immune protection, preferably via a neutralizing antibody response. Without being bound by theory, long-term immunity may comprise continued re-stimulation of antigen-specific B cells by sparse antigen expression during the latent period, thereby enhancing B cell immunity over time.
[0148] In some embodiments, the immune response provides protection to the subject from an immunogenic agent or source of an immunogenic agent. For example, the response can treat a subject with a tumor, such as by interfering with the metastasis of the tumor or reducing the number or size of the tumor. The immune response can be active and involve stimulating the subject's immune system, or a passive response to acquire immunity. A "repeatedly stimulated" immune response is a long-term immune response resulting from repeated production of antigens in the host that regularly and repeatedly stimulates the immune system.
[0149] In certain embodiments, an increased or enhanced immune response is an increase in the ability of a subject to fight disease (eg, a tumor, a viral infection, a bacterial infection, or a parasitic infection).
[0150] As used herein, the term "neutralizing antibody" refers to an antibody that protects target cells from pathogens or infectious particles by neutralizing any of their biological effects, preferably resulting in cessation or inhibition of pathogen infection of target cells. Neutralizing a pathogen renders the pathogen no longer infectious or pathogenic. Neutralizing antibodies are part of the humoral response of the acquired immune system against viruses, intracellular bacteria, and microbial toxins. In a specific embodiment, by specifically binding to the spike protein of SARS-CoV-2, neutralizing antibodies prevent viral particles from interacting with the ACE2 receptors of host cells that they may infect and destroy.
[0151] In embodiments, immune response includes sensitization, maintenance and / or strengthening of the subject's immune system. In embodiments, sensitization, maintenance and / or strengthening of the immune system can be achieved by administering two doses, preferably a single dose of the expected viral vector. In embodiments, sensitization, maintenance and / or strengthening of the immune system can be achieved by T cell response, preferably CD8+T cell response. In embodiments, sensitization, maintenance and / or strengthening of the immune system is achieved by T cell response (preferably long-term neutralizing antibody response) accompanied by neutralizing antibody response.
[0152] As used herein, the term "sensitized immune system" shall refer to the first contact of antigen-specific T helper cell precursors with antigens. T helper cells then interact with B cells to produce antibodies, which is crucial for T helper cells. When antigens are presented to antigen-specific naive lymphocytes in an immunogenic form that can induce an immune response, antigen-specific naive lymphocytes are sensitized. Subsequently, the sensitized cells will differentiate into effector cells or memory cells that can produce stronger and faster responses to the second and upcoming immune attack.
[0153] The term antigen-specific T cell shall refer to a CD8+ or CD4+ lymphocyte that recognizes a specific antigen. Typically, an antigen-specific T cell specifically binds to a specific antigen presented by a major histocompatibility complex (MHC) molecule, but does not bind to other antigens presented by the same MHC.
[0154] As used herein, the term "maintaining the subject's immune system" shall refer to one or more further contacts of the immune system with the same antigen or fragment thereof from the first contact, while sensitizing the immune system to the antigen or fragment thereof. Alternatively, the immune system may be maintained by further contact with another antigen or fragment thereof, causing the same disease as the antigen that first contacted the immune system. "Maintaining the immune system" may be determined, for example, by in vitro titration assays of neutralizing antibodies or animal models or any method known in the art without causing undue burden.
[0155] As used herein, the term "enhancing the immune system" shall refer to improving the immune system against a disease antigen. In one embodiment, it means maintaining the subject's immune system against a disease antigen for a longer period of time after the immunity generated by the first contact with the antigen begins to wane. In other embodiments, it means withdrawing the immune system from the sensitization of the immune system against an antigen or a fragment thereof with an antigen identical to the antigen or a fragment thereof. Alternatively, the immune system may be enhanced by further contact with another antigen or a fragment thereof that causes the same disease as the antigen that sensitized the immune system or maintained the immune system.
[0156] It can also provide for maintaining and enhancing the immune system after a subject has developed a disease caused by a disease antigen.
[0157] As used herein, the term "subject" shall refer to a living multicellular vertebrate, a category that includes humans and non-human mammals. The term encompasses both known and unknown individuals, and thus, a person handling a sample from a subject need not know who the subject is or even where the sample was obtained.
[0158] "Mouse subject" is interchangeable with "murine subject" and shall refer to a portion of the Murinae subfamily within the Muridae family. In embodiments, a murine subject shall exclude rats or any murine subject in which an IE2-deficient murine cytomegalovirus vector can be propagated or replicated. In embodiments, a murine subject is a house mouse (Mus musculus). A "non-mouse subject" is a subject excluding a mouse subject.
[0159] Another aspect of the present invention relates to a pharmaceutical composition comprising a replication-defective murine cytomegalovirus (MCMV) vector, wherein the vector preferably has a disrupted immediate early 2 (ie2) gene, rendering the vector replication-defective in a non-mouse subject, wherein the vector expresses a disease antigen, and wherein the composition is formulated for administration to a non-mouse subject.
[0160] As used herein, the term "administration" shall mean administration of an active compound or composition by any route known to those skilled in the art. Administration may be local or systemic. Examples of local administration include, but are not limited to, topical administration, subcutaneous administration, intramuscular administration, intrathecal administration, intrapericardial administration, intraocular administration, topical ophthalmic administration, or administration by inhalation to the nasal mucosa or lungs. Systemic administration includes, but is not limited to, intravenous and intraperitoneal routes, such as by directing intravascular administration to the arterial supply of a particular organ.
[0161] In embodiments, the pharmaceutical compositions described herein are formulated for administration to non-murine subjects. The form of the pharmaceutical composition is formulated or optimized for any route of administration in an effective amount sufficient to induce an antigen-specific immune response in a non-murine subject. In embodiments, the pharmaceutical composition is a vaccine, preferably formulated for single-dose administration.
[0162] An example of "formulated for administration to a non-mouse or non-murine subject" relates to an injection unit for use in humans, such as injection units typically used for SARS-CoV-2 vaccine products. One skilled in the art would be able to recognize a composition formulated for human use compared to a composition formulated for use in mice. In embodiments, a common injection formulation or a vial used to prepare a syringe for human injection may be considered a composition formulated for non-mouse use.
[0163] "Effective amount" shall mean an amount sufficient to achieve the desired effect in the subject being treated. During treatment, an effective amount of a composition (e.g., a vaccine) may be administered in a single dose or multiple doses. However, the effective amount of the compound will depend on the compound used, the subject being treated, the severity and type of the disease, and the mode of administration of the compound.
[0164] In one embodiment, "single dose" refers to an effective amount of a composition for inducing an immune response to a disease antigen, wherein the immune response can be sensitization, maintenance or enhancement of an immune response. In a preferred embodiment, a single dose vaccine comprising an IE2-deficient murine cytomegalovirus vector should be able to sensitize, maintain and enhance the immune system due to its replication defect and latency in the host. This constitutes a periodic and repetitive stimulation of the immune system by repeatedly producing antigens in the host.
[0165] As used herein, the term "vaccine" is an immunogenic composition that can be administered to a mammal (e.g., a human) to confer immunity (e.g., active immunity) to a disease or other pathological condition. Vaccines can be used for prevention or treatment. Therefore, vaccines can be used to reduce the likelihood of contracting a disease (e.g., a tumor or pathological infection) or reduce the severity of the symptoms of a disease or condition, limit the progression of a disease or condition (e.g., a tumor or pathological infection), or limit the recurrence of a disease or condition (e.g., a tumor). In a specific embodiment, the vaccine is a replication-deficient CMV expressing a heterologous antigen (e.g., a tumor-associated antigen derived from the lung, prostate, ovary, breast, colon, cervix, liver, kidney, bone, or melanoma).
[0166] The pharmaceutical composition for use according to the present invention can be prepared in a conventional manner using one or more physiologically acceptable carriers (including excipients, carriers and / or adjuvants) to facilitate the processing of the active agent into a preparation that can be used for medicine. Suitable preparations depend on the target subject (e.g., human or non-human animal) and the selected route of administration.
[0167] Pharmaceutically acceptable carriers, excipients, solvents or adjuvants used herein are nontoxic to cells or mammals exposed thereto at the doses and concentrations employed. Typically, a physiologically acceptable carrier is an aqueous pH buffer solution. Examples of physiologically acceptable carriers include, but are not limited to, buffers such as phosphates, citrates and other organic acids; antioxidants, including but not limited to ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as but not limited to serum albumin, gelatin or immunoglobulins; hydrophilic polymers, such as but not limited to polyvinyl pyrrolidone; amino acids, such as but not limited to glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates, including but not limited to glucose, mannose or dextrin; chelating agents, such as but not limited to EDTA; sugar alcohols, such as but not limited to mannitol or sorbitol; salt-forming counterions, such as but not limited to sodium; and / or nonionic surfactants, such as but not limited to TWEEN, polyethylene glycol (PEG) and PLURONICS.
[0168] The phraseology and terminology used herein is for descriptive purposes only and should not be regarded as limiting. The use of "including," "comprising," or "having," "containing," "involving," and variations thereof as used herein are intended to encompass the items listed thereafter and their equivalents.
[0169] Unless otherwise indicated, technical terms will be used according to conventional usage. The definition of commonly used terms in molecular biology can be found in the following literature: Benjamin Lewin, Genes V, published by Oxford University Press in 1994 (ISBN0-19-854287-9); Kendrew et al. (eds.), "Encyclopedia of Molecular Biology", published by Blackwell Science Ltd. in 1994 (ISBN0-632-02182-9); and Robert A.Meyers (ed.), "Molecular Biology and Biotechnology: A Comprehensive Desk Reference", published by VCH Publishers, Inc. in 1995 (ISBN1-56081-569-8).
[0170] Sequence Listing:
[0171]
[0172]
[0173]
[0174] BRIEF DESCRIPTION OF THE DRAWINGS
[0175] The following drawings are used to describe certain embodiments of the present invention but not to limit its scope.
[0176] Brief description of the drawings:
[0177] Figure 1 : Different types of functional antigen-presenting cells induced by different cytokines from human monocytes infected with MCMV.
[0178] Figure 2 : The ability of MCMV to replicate in human cells.
[0179] Figure 3 : Permissiveness of retinal pigment epithelial cells to MCMV.
[0180] Figure 4 : The m129 and m131 mutants could not explain the RPE growth phenomenon. Therefore, these genes are not essential for RPE cell growth.
[0181] Figure 5 : Growth potential of RPE cells infected with different MCMV mutants.
[0182] Figure 6 : MCMV does not proliferate in MoDCs.
[0183] Figure 7 : Antigen-specific CD8 responses are stronger against cells infected with MCMV than against cells infected with HCMV.
[0184] Figure 8 : Schematic representation of the recombinant MCMV vector genome.
[0185] Fig. 9 : Weight loss and scores of MCMV-immunized hamsters after SARS-CoV-2 challenge.
[0186] Fig.10 : Weight loss and scores of MCMV-immunized hamsters after SARS-CoV-2 challenge.
[0187] Fig.11 : Infection with MCMV-S induces antibody responses in rats.
[0188] Fig.12 : Immature monocytic dendritic cells are susceptible to MCMV infection.
[0189] Fig.13 : Mature monocytic dendritic cells are susceptible to MCMV infection.
[0190] Fig.14 : Monocyte dendritic cells are susceptible to MCMV infection.
[0191] Fig.15 : M2 macrophages are susceptible to MCM infection.
[0192] Fig.16 : MCMV S Long-term immune response to coronavirus variants after immunization.
[0193] Fig.17 : Daily body weight loss and clinical scores after viral challenge with D614G strain.
[0194] Detailed description with attached drawings:
[0195] Figure 1: Different types of functional antigen-presenting cells induced by different cytokines from human monocytes infected with MCMV. (A) Human monocytes were isolated from healthy donors. Different cytokines were used to induce differentiation into different types of functional antigen-presenting cells. (B) Recombinant MCMV carrying a GFP reporter gene controlled by the ie1 / 3 (immediate early) promoter and mCherry controlled by the scp (late) promoter. Monocyte-derived classical dendritic cells were obtained and infected with MCMV. Early and late gene vector transgenes were expressed. (C) Monocyte-derived plasmacytoid-derived DCs were obtained. Early and late gene vector transgenes were expressed. Strong cytokine responses were found after MCMV infection. (D) Monocyte-derived Langerhans-like cells were obtained. Langerhans protein expression and phenotype corresponded to primary Langerhans cells. Early and late gene vector transgenes were expressed.
[0196] Figure 2 : The ability of MCMV to replicate in human cells. Six cell lines were tested for MCMV replication. The infectious units in the supernatant steadily decreased. The results showed no viral growth in any of the human cell lines.
[0197] Figure 3 : Retinal pigment epithelial cells are allowed to MCMV. MCMV wild-type virus grows in two independent cell lines based on retinal pigment epithelium: (A) RPE1_NEW ATCC 121119 (B) ARPE19_121119. This is in sharp contrast to previous reports, that is, MCMV will not grow on RPE-I unless the viral gene (M112 / M113) adapts to this, allowing growth on this cell type (Schumacher, U., et al. M112 / M113 coding region mutations promote mouse cytomegalovirus replication in human cells (mutations in the M112 / M113-coding region facilitate murinecytomegalovirus replication in human cells) (2010) Journal of Virology, 84 (16), pp.7994-8006.DOI: 10.1128 / JVI.02624-09). We tested the virus used in the above paper (MCMVC3X-GFP) and reproduced their findings. We believe there are two genes that are potentially different between our MCMVdFP and their MCMVC3X-GFP: m129 / m131, also known as MCK-2 (mutated in the C3X clone) and IE2 (due to the GFP insertion).
[0198] Figure 4: The m129 and m131 mutants cannot explain the RPE growth phenomenon. Therefore, these genes are not required for RPE cell growth. C3X has a frameshift mutation that mutates the viral ORFs m129 and m131. Two independent viral mutants were tested for growth in RPE-I cells. The parental C3X clone (w / o GFP) is shown on the right and is able to grow.
[0199] We generated a virus with a targeted frameshift mutation in the m129 / m131 gene to match the mutation in the C3X clone and with GFP expressed outside of IE2. We compared its growth to that of the parental virus expressing GFP at the same position and without the frameshift. Both viruses were able to grow in RPE-I with very similar kinetics. Therefore, the mutation in m129 / m131 is not responsible for the growth defect in RPE-I.
[0200] Figure 5 : Growth potential of RPE cells infected with different MCMV mutants (i.e., c3x mutant and IE2 mutant). C3X-GFP Deep sequencing was performed and revealed a deletion in the noncoding region of exon 1 of IE2. The deletion included the TATA box of the gene. Therefore, we thought that the deletion of IE2 might lead to the loss of MCMV replication in human RPE-I cells. This was confirmed using a mutant virus in which the genetic sequence of IE2 was disrupted.
[0201] Figure 6 : MCMV does not proliferate in MoDCs. Dendritic cells derived from primary human monocytes were tested for MCMV replication. A steady decline in infectious units was observed in the supernatant. Results showed no viral growth in any of the human cell lines tested in this screen, but did show viral growth in mouse fibroblasts.
[0202] Figure 7 : Antigen-specific CD8 responses are stronger against cells infected with MCMV than against cells infected with HCMV. (A) Schematic diagram of the experimental steps. (B) and (C) *NLVPMVATV is an immunodominant antigenic peptide derived from the pp65 antigen of HCMV. Therefore, it is present in transgenic MCMV-NLV and the HCMV clones used. HCMV-TB40E lacks US2, US3, US6-immune escape genes, which downregulate HLA-I expression on virus-infected cells, resulting in CD8 T cell recognition of infected cells. KL7-SE is a wild-type HCMV with all genes in it.
[0203] Figure 8: Schematic representation of the recombinant MCMV vector genome. (A) MCMV-S genome map. (B) The location where the SARS-CoV-2 spike ORF is inserted into ie2.
[0204] Fig. 9 : Weight loss and scores of MCMV-immunized hamsters after SARS-CoV-2 challenge. S , MCMV WT Hamsters were immunized intraperitoneally with 1% SARS-CoV-2 or PBS. Seven weeks later, hamsters were infected intranasally with 2000 PFU of SARS-CoV-2 (D614G strain). Viruses with disrupted IE2 sequences were tested for immunogenicity and immune protection in hamsters. Mice vaccinated with MCMV expressing SARS-CoV-2 spike instead of IE2 were challenged with SARS-CoV-2, and weight loss and clinical scores were monitored. Our data show that vaccinated hamsters are protected from disease.
[0205] Fig.10 : Weight loss and scores of MCMV-immunized hamsters after SARS-CoV-2 challenge. (A) Neutralization assay using SARS-CoV-2D614G. Two hamsters did not show any antibody response. Neutralization assays were performed according to published protocols (Kim et al., 2022, Cell. Mol. Immunol.). (B) and (C) Neutralization assays using MCMV-immunized hamsters. S , MCMV WT Hamsters were immunized intraperitoneally with 1% or PBS. 14 weeks later, hamsters were infected intranasally with 2000 PFU of SARS-CoV-2 (strain D614G). All hamsters showing S-specific antibodies were protected from SARS-CoV-2 disease. (D) No infectious SARS-CoV-2 was found in lung homogenates of hamsters showing S-specific antibodies. (E) Serum titers in ELISA assays with the indicated spike mutants (SARS-CoV-2, α, κ, β) are shown 4 weeks after intraperitoneal vaccination with a single dose of MCMV-Spike vaccine.
[0206] Fig.11 : Infection with MCMV-S induces antibody responses in rats. (A) Schematic representation of the recombinant MCMV vector (MCMV-S). The location of the SARS-CoV-2 spike ORF insertion into MCMV ie2. (B) Setup of the rat experiment. (C) Wistar female rats were immunized intraperitoneally with 106 PFU / rat of the spike-expressing MCMV vector (MCMV-S) or WT-MCMV as a control. Blood was collected six weeks after immunization for serum analysis. Spike-specific IgG was assessed by ELISA (n=5).
[0207] Fig.12 : Immature monocytic dendritic cells are susceptible to MCMV infection. MCMV-WT is shown as a black background in each figure. HCMV TB40E-iEMNG, MCMV-ie2-mCherry, MCMV-ie1 / 3-GFP (nMOI 2) are also shown. 24hpi (replicate, representative figure) were performed. Human mo-DCs were generated from monocytes isolated from healthy CMV-negative blood donors. 1000UI / mL human GM-CSF and 1000UI / mL human IL-4 were used for cytokine differentiation for 5 days. To measure the reporter gene positive population, mo-DCs were harvested and analyzed by flow cytometry. Live single cells were gated.
[0208] Fig.13 : Mature monocytic dendritic cells are susceptible to MCMV infection. MCMV-WT is shown as a black background in each figure. HCMV TB40E-iEMNG, MCMV-ie2-mCherry, MCMV-ie1 / 3-GFP (nMOI 2) are also shown. 24hpi (replicate, representative figure) was performed. Human mo-DCs were generated from monocytes isolated from healthy CMV-negative blood donors. 1000UI / mL human GM-CSF and 1000UI / mL human IL-4 were used for cytokine differentiation for 5 days. To induce maturation, mo-DCs were stimulated for 24 hours using 200UI / mL human TNFα, 10ng / mL human IL-1β, 1000UI / mL human IL-6 and 1ug / mL PGE2.
[0209] Fig.14 :Monocyte-plasmacytoid dendritic cells are susceptible to MCMV infection. MCMV-WT is shown as a black background in each figure. HCMV TB40E-iEMNG, MCMV-ie2-mCherry, MCMV-ie1 / 3-GFP (nMOI 2) are also shown. 24hpi (repeat, representative figure) was performed. Human mo-pDC was generated from monocytes isolated from healthy CMV-negative blood donors. The cells were cultured in medium containing Flt3-L (100ng / mL) for 5 days, and then the medium was replaced with Flt3-L+CpG-A (2336) ODN (5μg / mL) until the 9th day. In order to verify the mo-pDC phenotype, staining antibodies with CD304 and CD123 were performed.
[0210] Fig.15:M2 macrophages are susceptible to MCM infection. MCMV-WT is shown as a black background in each figure. HCMV TB40E-iEMNG, MCMV-ie2-mCherry, MCMV-ie1 / 3-GFP (nMOI 5) are also shown. 24hpi (repeat, representative figure) was performed. Human mo-DCs were generated from monocytes isolated from healthy CMV-negative blood donors. 20ng / mL human M-CSF was used for cytokine differentiation for 5 days. Subsequently, cells were stimulated with 1000UI / mL human IL-4, 10UI / mL human IL-13, and 1000UI / mL human IL-6 for 24 hours.
[0211] Fig.16 : MCMV S Long-term immune response to coronavirus variants after immunization. (A) Schematic diagram of the experimental setup for the long-term challenge experiment. (B) Neutralization titers (pVNT50) of pseudotyped viruses against Delta and Omicron variants. Each symbol represents the following: closed represents the short-term vaccinated cohort, open represents the long-term vaccinated cohort. (CD) pVNT50 values of individual hamsters 4 weeks or 3 months after vaccination against (C) Delta variant or (D) Omicron variant. (E) 3-month time course kinetics of neutralizing antibody response against the live D614G variant. Each symbol represents an individual hamster, and hamsters marked with X represent hamsters that were not protected after virus challenge.
[0212] Fig.17 : Daily body weight loss (A) and clinical scores (B) after viral challenge with D614G strain. Example
[0213] The following examples are specific embodiments of the present invention but are not intended to limit the scope thereof.
[0214] As shown herein, the mouse cytomegalovirus (MCMV) vaccine vector platform elicits a robust immune response in non-mouse or non-murine species. MCMV is considered to be strictly species-specific, with extremely limited replication in cells that do not belong to its natural host species. We have comprehensively tested the growth of MCMV in human cells and determined that (contrary to reports in the literature) it is able to grow in human retinal pigment epithelium (RPE).
[0215] We identified a viral gene that is essential for MCMV replication in the RPE but not for its growth in murine cells. The gene in question is called immediate early 2 (ie2). We generated recombinant viruses lacking ie2 and verified that they do not grow in RPE cells. Thus, we generated an MCMV that is able to grow naturally in murine cells but acts as a single-cycle safe viral vector in non-mouse / non-murine / human cells.
[0216] Our approach is qualitatively different from the published evidence and enables MCMV-based vaccine vectors to protect against infectious pathogens. As an example of vaccine effectiveness and applicability, representative examples of HCMV antigens encoded by MCMV vectors and coronavirus antigens tested in vivo are shown below. We show that this vector eliminates the biosafety concerns posed by the ability of MCMV to grow in human retinal epithelial cells.
[0217] Example 1: Different cytokines are used to induce human monocytes to differentiate into different types of functional antigen presenting cells, and infect these antigen-presenting cells with MCMV.
[0218] Different types of functional antigen-presenting cells induced by different cytokines from human monocytes infected with MCMV. Human monocytes were isolated from healthy donors. Different cytokines were used to induce differentiation into different types of functional antigen-presenting cells ( Figure 1 A). Recombinant MCMV carries the GFP reporter gene controlled by the ie1 / 3 (immediate early) promoter and mCherry controlled by the scp (late) promoter. Monocyte-derived classical dendritic cells were obtained and infected with MCMV. Expression of early and late gene vector transgenes ( Figure 1 B). Obtaining monocyte-derived plasmacytoid-derived DCs. Expressing early and late gene vector transgenes. Strong cytokine responses were found after MCMV infection ( Figure 1 C). Obtain monocyte-derived Langerhans-like cells. Langerhans protein expression and phenotype correspond to primary Langerhans cells. Expressing early and late gene vector transgenes ( Figure 1 D).
[0219] Example 2: Testing the ability of MCMV to replicate in human cells
[0220] Follow the steps in the following scenario:
[0221] 1) 40k cells were seeded one day before infection 2) MCMVWT was infected at MOI 1 at 37°C for one hour 3) The cells were washed twice with PBS and replaced with new medium 4) The infected cells were incubated at 37°C 5) SN was absorbed at the indicated time points 6) The infectious virus was titrated on MEF cells. Figure 2As shown, 6 cell lines were tested for MCMV replication. The infectious units in the supernatant steadily decreased. The results showed no viral growth in any human cell line.
[0222] Example 3: Retinal Pigment Epithelial Cells Are Permissive for MCMV Growth
[0223] MCMV wild-type virus was isolated from retinal pigment epithelial cells based on RPE1_NEW ATCC 121119 ( Figure 3 A) ARPE19_121119( Figure 3 B) grows in two independent cell lines. This is in sharp contrast to previous reports, that is, MCMV will not grow on RPE-I, unless the viral gene (M112 / M113) adapts to this, allowing growth on this cell type (Schumacher, U., et al. M112 / M113 coding region mutations promote mouse cytomegalovirus replication in human cells (mutations in the M112 / M113-coding region facilitate murine cytomegalovirus replication in human cells) (2010) Journal of Virology, 84 (16), pp.7994-8006.DOI: 10.1128 / JVI.02624-09). We tested the virus (MCMVC3X-GFP) used in the above paper and summarized and re-stated their findings. We think there may be two genetic differences between our MCMVdFP and their MCMVC3X-GFP: m129 / m131, also known as MCK-2 (mutated in the C3X clone) and IE2 (due to the GFP insertion).
[0224] Example 4: M129 and m131 are not essential for RPE cell growth
[0225] We generated a virus with a targeted frameshift mutation in the m129 / m131 genes to match the mutation in the C3X clone and with GFP expressed outside of IE2. We compared its growth to the parental virus expressing GFP at the same position and without the frameshift. Both viruses were able to grow in RPE-I with very similar kinetics. Therefore, the mutations in m129 / m131 are not responsible for the RPE-I growth defect. Therefore, these genes are not required for RPE cell growth. C3X has a frameshift mutation that mutates the viral ORFsm129 and m131. Two independent viral mutants with such mutations were tested for growth in RPE-I cells. The parental C3X clone (w / o GFP) was grown as Figure 4 As shown in A, it can grow.
[0226] Example 5: Infection with MCMVC 3X - GFP and MCMV IE2KO Phenomenon of RPE cells
[0227] Growth potential of RPE cells infected with different MCMV mutants (i.e., c3x mutant and IE2 mutant). C3X-GFP Deep sequencing was performed and revealed a deletion in the noncoding region of exon 1 of IE2. The deletion included the TATA box of the gene. Therefore, we thought that the deletion of IE2 might lead to the loss of MCMV replication in human RPE-I cells. This was confirmed using a mutant virus in which the genetic sequence of IE2 was disrupted.
[0228] ie2 gene sequence (SEQ ID NO: 1):
[0229] ccgtgctgattcatatgccatatgagtgtattagggggctttccgcttgggaaattgggtaaaaagtccccgtattactcacatagggggcgtttggctttgcaaattaggggatttcagtgcatttggcattaaaaactattggttctagtcataaaacgggcggagttAACCATATAAAAGCTGTCCCCCATGCCATTCGA GCCCAGAGCAGGACGGA CCGCGGCTCGATACGACCCTATCTACGTT aacgagcgggtgaacggagccccccaggccgggtaaggttgcattgggctcggctatgggacggggatttggcccggtactttaatatgggtggggtct
[0230] The uppercase sequence is the deletion sequence of the 5' region of the IE2 gene in C3X-GFP MCMV, the bold sequence is the TATA box sequence, and the underlined sequence is exon 1.
[0231] Example 6: MCMV does not proliferate in dendritic cells derived from primary human monocytes.
[0232] Dendritic cells derived from primary human monocytes were tested for MCMV replication. Figure 6 As shown, a steady decrease in infectious units was observed in the supernatant. The results showed that the viruses tested in this screen did not grow in any human cell line but grew in mouse fibroblasts.
[0233] Example 7: Antigen-specific CD8 responses are stronger against MCMV-infected cells than against HCMV-infected cells
[0234] The schematic diagram of the experimental steps is as follows Figure 1As shown in A. *NLVPMVATV is an immunodominant antigenic peptide derived from the pp65 antigen of HCMV. Therefore, it is present in the transgenic MCMV-NLV and the HCMV clones used. HCMV-TB40E lacks US2, US3, US6-immune escape genes, resulting in downregulation of HLA-I expression in virus-infected cells, thereby leading to CD8 T cell recognition of infected cells. KL7-SE is a wild-type HCMV ( Figure 7 B and 7C).
[0235] Example 8: Weight loss and scores of MCMV-immunized hamsters after SARS-CoV-2 challenge.
[0236] Using MCMV S , MCMV WT Hamsters were immunized intraperitoneally with 1% or PBS. Seven weeks later, hamsters were infected intranasally with 2000 PFU of SARS-CoV-2 (D614G strain). Viruses with disrupted IE2 sequences were tested for immunogenicity and immune protection in hamsters. Vaccination of mice with MCMV expressing SARS-CoV-2 spike instead of IE2 was challenged with SARS-CoV-2, and weight loss and clinical scores were monitored ( Fig. 9 A and 9B). Our data indicate that vaccinated hamsters were protected from disease.
[0237] Example 9: Weight loss and scores of MCMV-immunized hamsters after SARS-CoV-2 challenge .
[0238] Neutralization test was performed with SARS-CoV-2D614G. 2 hamsters did not show any antibody response ( Fig.10 A). Neutralization assays were performed according to published protocols (Kim et al., 2022, Cell. Mol. Immunol.). S , MCMV WT Hamsters were immunized intraperitoneally with 1% or PBS. 14 weeks later, hamsters were infected intranasally with 2000 PFU of SARS-CoV-2 (D614G strain). All hamsters that showed S-specific antibodies were protected from SARS-CoV-2 disease ( Fig.10 B and 10C). No infectious SARS-CoV-2 was found in lung homogenates of hamsters that displayed S-specific antibodies ( Fig.10 D). Shown are serum titers in ELISA assays with the indicated spike mutants (SARS-CoV-2, α, κ, β) 4 weeks after a single dose of MCMV-Spike vaccine administered intraperitoneally ( Fig.10 E).
[0239] Example 10: Infection with MCMV-S induces an antibody response in rats
[0240] To explore the potential of MCMV-S vectors for cross-species immunization, rats were immunized and their blood was collected for serum analysis. MCMV, as a species-specific virus, can infect rats, but cannot fully replicate, resulting in infection failure, so the purpose of this experiment is to observe whether infection will lead to antibody responses to vector antigens. Shown here are data from the endpoint time point (42dpi). All rats showed antibody responses to the SARS-COV-2S protein.
[0241] The schematic diagram of the recombinant MCMV vector (MCMV-S) is shown in Fig.11 A. The SARS-CoV-2 spike ORF was inserted into the MCMVie2 site. The rat experiment was set up as Fig.11 As shown in B. Wistar female rats were inoculated intraperitoneally with 106 PFU / rat of MCMV vector expressing spike (MCMV-S) or WT-MCMV as a control. Blood was collected six weeks after immunization for serum analysis. Spike-specific IgG was evaluated by ELISA (n=5) ( Fig.11 C).
[0242] Example 11: Susceptibility of human monocytes to MCMV infection
[0243] To explore the potential of MCMV vectors to infect human cells and induce foreign antigen expression in antigen-presenting cells, human monocyte-derived cells were generated from healthy CMV-negative human blood donors. After isolation of monocytes by magnetic bead sorting, immature Mo-DC, mature Mo-DC, mo-plasmacytoid DC (mo-pDC), and M2 macrophages were obtained by cytokine stimulation. For immature moDC, 1000 UI / mL human GM-CSF and 1000 UI / mL human IL-4 were used for 5 days. For mature moDC, 200 UI / mL human TNFα, 10 ng / mL human IL-1β, 1000 UI / mL human IL-6, and 1 ug / mL PGE2 were additionally used for stimulation for 24 hours. For mo-PDC, cells were cultured in medium containing Flt3-L (100 ng / mL) for 5 days, and then the medium was changed to Flt3-L+CpG-A(2336)ODN (5 μg / mL) until day 9. For M2 macrophages, cytokine differentiation was performed using 20 ng / mL human M-CSF for 5 days, followed by stimulation with medium containing 1000 UI / mL human IL-4, 10 UI / mL human IL-13, and 1000 UI / mL human IL-6 for 24 hours. Then, cells were infected with the MCMV reporter gene to monitor the expression of fluorescent proteins driven by the endogenous promoter. Immature Mo-DCs, mature Mo-DCs, and M2 macrophages were infected with human CMV (HCMV TB40E-iEMNG) and mouse CMV (MCMV-ie2-mCherry, MCMV-ie1 / 3-GFP), respectively, as shown in Figure 2. Figure 12-15 As shown, all were susceptible to MCMV infection.
[0244] Example 12: MCMV S Long-term immune response to coronavirus variants after immunization
[0245] Infection in the body:
[0246] Syrian hamsters (8-9 weeks old, male) were immunized with 106 PFU of recombinant MCMVS or MCMVWT diluted in PBS, or PBS (200 μL per animal) by intraperitoneal injection. Blood was collected at designated time points to control the immune status of the vaccinated animals.
[0247] After the specified time point, the challenge experiment was performed. The vaccinated hamsters were anesthetized with a solution of ketamine (100 mg / kg) and medetomidine (1 mg / mL). Thereafter, the anesthetized animals were infected intranasally with 103 PFU SARS-CoV-2 (50 μL per nasal cavity). 45 minutes after anesthesia, the sleeping hamsters were awakened by administering 100 μL of a NaCl solution of atipamezole (1.7 mg / kg). All infected hamsters were monitored for the development of virus-related symptoms and scored daily.
[0248] from Fig.16 (in particular Fig.16 C and Fig.16 D) It can be concluded that the pVNT50 values for individual hamsters 4 weeks or 3 months after vaccination against the (C) Delta variant or the (D) Omicron variant indicate an increase in antibody titers over time. This is an interesting and unexpected result, suggesting that antigen-specific immunity may not wane or decrease over time after administration of a single dose of the vaccine mCMV vector, but may increase, thereby reducing the need for booster immunizations, such as is the case with mRNA vaccines.
[0249] In vitro Virus Neutralization Titer (VNT) Measurement:
[0250] Serum neutralization assay was performed as previously described (Y. Kim et al., 2022). In brief, serum was heat-inactivated at 56°C for 30 min. Then, the serum was serially diluted in a 1:2 ratio and then incubated with SARS-CoV-2 (1,000 PFU / mL) for one hour at room temperature. Vero-E6 cells (density of 2 × 10 in 96-well plates) were plated with 4 The serum / virus mixture was inoculated in 1 well ( / well) for 1 hour. After the inoculum was removed, the subsequent steps were the same as the plaque assay. The serum titer that resulted in a 50% reduction in viral plaques (VNT50) was analyzed by nonlinear regression analysis using GraphPad Prism.
[0251] Pseudovirus Neutralization Titer (pVNT) Measurement:
[0252] Pseudovirus neutralization assays were performed as described in previous publications (Hoffmann et al., 2021; Y. Kim et al., 2022). For neutralization experiments, pseudotyped particles and serum dilutions were mixed in a 1:1 ratio and incubated at 37 °C for 60 min before inoculation onto VeroE6 cells grown in 96-well plates. GFP expression was measured 22-24 h after infection using Incucyte S3 (Sartorius, Goettingen, Germany). Similar to VNT50, the serum titer (pVTN50) that resulted in a 50% reduction in GFP signal was analyzed by nonlinear regression analysis using GraphPad Prism.
[0253] To the best of the inventors' knowledge, the data demonstrate for the first time that a CMV-based vaccine vector provides stable and durable humoral immunity in a species that is not the virus's natural host, thereby demonstrating from proof of principle that MCMV vectors can be used as carriers of antigens targeting human pathogens in a clinical setting.
Claims
1. A method of inducing an antigen-specific immune response in a subject using a replication-deficient murine cytomegalovirus (MCMV) vector, wherein: The subject is not a mouse, and wherein the vector expresses a disease antigen.
2. Use of a vector according to the preceding claim, wherein: An open reading frame for the disease antigen is inserted into the vector to replace any non-essential viral genomic sequences.
3. Use of a vector according to any one of the preceding claims, wherein The vector has a disrupted immediate early 2 (ie2) gene, rendering the vector replication defective in non-mouse subjects.
4. Use of a vector according to any one of the preceding claims, wherein The ie2 gene is disrupted by deleting the ie2 gene or a portion thereof, preferably by deleting the TATA box or deleting the ie2 open reading frame or a portion thereof.
5. Use of a vector according to the preceding claim, wherein The open reading frame of the disease antigen is inserted into the vector to replace the ie2 open reading frame or a portion thereof.
6. Use of a vector according to any one of the preceding claims, wherein The open reading frame of the disease antigen is expressed by an immediate early MCMV promoter, a constitutive promoter or an inducible MCMV promoter.
7. Use of a vector according to any one of the preceding claims, wherein The subject is a human or a non-human animal.
8. Use of a vector according to any one of the preceding claims, wherein The immune response includes a neutralizing antibody response or a T cell response to a disease antigen, or sensitizing, maintaining and / or enhancing the subject's immune system.
9. Use of a vector according to any one of the preceding claims, wherein The disease antigens include antigens or fragments of pathogenic viruses, bacteria, parasites and / or cancer cells.
10. Use of a vector according to the preceding claim, wherein The viral antigens include antigens from coronavirus, influenza virus, herpes virus, polyomavirus, papillomavirus, orthomyxovirus, paramyxovirus, picornavirus, parvovirus, reovirus, rhabdovirus, togavirus, African swine fever, adenovirus, coxsackievirus, arenavirus, retrovirus, alphavirus, pestivirus, flavivirus or arbovirus, preferably the spike, envelope, membrane and / or nucleoprotein of SARS-CoV-2 or any part thereof.
11. Use of a vector according to any one of the preceding claims, wherein The disease antigens are: a. Bacterial antigens, preferably including antigens from Mycobacterium, Listeria, Chlamydia, Rickettsia, Yersinia, Helicobacter pylori, Legionella, Streptococcus, Staphylococcus, Neisseria or Salmonella, or b. Parasite antigens, preferably including antigens from Plasmodium or Trypanosoma.
12. A pharmaceutical composition comprising a replication-deficient murine cytomegalovirus (MCMV) vector suitable for inducing an antigen-specific immune response in a subject, wherein: The vector expresses a disease antigen, and wherein the composition is formulated for administration to a non-mouse subject, preferably, the non-mouse subject comprises a human or veterinary acceptable carrier, excipient, vehicle and / or adjuvant.
13. A pharmaceutical composition according to the preceding claim, wherein The vector has a disrupted immediate early 2 (ie2) gene, rendering the vector replication defective in non-mouse subjects.
14. The pharmaceutical composition according to any one of claims 12-13, wherein The pharmaceutical composition is a vaccine, preferably, the vaccine is formulated for single-dose administration.
15. Use of the pharmaceutical composition according to any one of claims 12 to 14 for inducing an antigen-specific immune response to an expressed disease antigen in a non-mouse subject.
